MedTrace Logo

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

NCT06283550 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2026-02-03

No results posted yet for this study

Summary

This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

Conditions

  • Chronic Hand Eczema

Interventions

DRUG

Abrocitinib 200 mg

Abrocitinib will be available in 100 mg strength tablet

DRUG

Abrocitinib 100 mg

Abrocitinib will be available in 100 mg strength tablet

DRUG

Placebo

Placebo tablet

Sponsors & Collaborators

  • Innovaderm Research Inc.

    lead OTHER

Principal Investigators

  • Robert Bissonnette, MD · Innovaderm Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2025-06-18
Completion
2025-11-03
FDA Drug
Yes

Countries

  • Canada
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06283550 on ClinicalTrials.gov